In the SUSTAIN clinical trial, infusion-related reactions (defined as occurring within 24 hours of infusion) were observed in 2 (3%) patients treated
Download this resource designed to guide you through dosing and administering ADAKVEO.
Brochure that provides suggested strategies for engaging with patients at their ADAKVEO infusion appointments and details safety considerations, including management considerations for infusion-related reactions and the most common adverse reactions.
Educational information for physician offices and hospital outpatient clinics, including a list of relevant codes and sample letters of appeal and medical necessity.
Sample annotated CMS claim form for physician offices (CMS-1500) with suggestions for each box for miscellaneous billing and coding.
Sample annotated CMS claim form for hospital outpatient (CMS-1450/UB-04) with suggestions for each box for miscellaneous billing and coding.
The Novartis Oncology Service Request Form is used to assess patient eligibility for Novartis Oncology programs, including financial assistance and free trial offers.
A downloadable brochure detailing available support for your patients and caregivers available through ADAKVEO Support at PANO.
A video that provides patients with helpful tips for discussing sickle cell disease and ADAKVEO with their doctor
A video created to educate patients on how ADAKVEO works in the body
A downloadable brochure to help your patients with sickle cell disease navigate treatment with ADAKVEO
A program offering helpful resources for your patients taking ADAKVEO. After registering, they will receive tips and information to help support them on their treatment journey
A tool to help patients remember everything they want to say about how they are feeling, how treatment is going, and any questions they may have
ADAKVEO® (crizanlizumab-tmca) is indicated to reduce the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients, aged 16 years and older, with sickle cell disease.
In the SUSTAIN clinical trial, infusion-related reactions (defined as occurring within 24 hours of infusion) were observed in 2 (3%) patients treated with ADAKVEO 5 mg/kg. Monitor patients for signs and symptoms of infusion-related reactions, which may include fever, chills, nausea, vomiting, fatigue, dizziness, pruritus, urticaria, sweating, or shortness of breath or wheezing. Discontinue ADAKVEO infusion for severe reactions and institute appropriate medical care.
Laboratory Test Interference: Platelet Counts
Interference with automated platelet counts (platelet clumping) has been observed following administration of ADAKVEO, in particular, when blood samples were collected in tubes containing EDTA.
Run blood samples within 4 hours of blood collection or collect blood samples in tubes containing citrate. When needed, estimate platelet count via peripheral blood smear.
Based on animal data, ADAKVEO has the potential to cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. ADAKVEO should only be used during pregnancy if the expected benefit to the patient justifies the potential risk to the fetus.
Most Common Adverse Reactions
The most frequently reported adverse reactions (≥10%) in patients treated with ADAKVEO were nausea (18%), arthralgia (18%), back pain (15%), and pyrexia (11%).
Other Clinically Important Adverse Reactions
Clinically relevant adverse reactions (all grades) that were reported in <10% of patients treated with ADAKVEO included: oropharyngeal pain, abdominal pain (abdominal pain, upper abdominal pain, lower abdominal pain, abdominal discomfort, and abdominal tenderness), diarrhea, vomiting, pruritus (pruritus and vulvovaginal pruritus), musculoskeletal chest pain, myalgia, infusion-site reaction (infusion-site extravasation, infusion-site pain, and infusion-site swelling), and infusion-related reaction.
Please see full Prescribing Information.